Compare CC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | PVLA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2014 | 2013 |
| Metric | CC | PVLA |
|---|---|---|
| Price | $12.67 | $175.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $16.20 | ★ $228.40 |
| AVG Volume (30 Days) | ★ 2.4M | 222.4K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,638,000,000.00 | $42,810,000.00 |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.36 | ★ 65.28 |
| 52 Week Low | $10.44 | $72.23 |
| 52 Week High | $28.67 | $163.75 |
| Indicator | CC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 72.50 |
| Support Level | N/A | $106.07 |
| Resistance Level | $16.26 | N/A |
| Average True Range (ATR) | 0.64 | 9.69 |
| MACD | 0.05 | 4.79 |
| Stochastic Oscillator | 18.75 | 97.58 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.